EISMEA
VC Fund
EISMEA is a VC fund focused on Health Care and Biotechnology.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries EISMEA invests in
Health CareBiotechnologyMedicalManufacturingMedical Device
Stages EISMEA invests in
GrantSeedVenture - Series Unknown
Countries EISMEA invests in
DenmarkItalyFranceIsraelFinland
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Monique Calisti
|
|||
Investment Focus
Industry
- Health Care 3 (43%)
- Biotechnology 3 (43%)
- Medical 2 (29%)
- Manufacturing 2 (29%)
- Medical Device 2 (29%)
Stage
- Grant 5 (71%)
- Seed 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- Denmark 2 (29%)
- Italy 1 (14%)
- France 1 (14%)
- Israel 1 (14%)
- Finland 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cristian Dascalu
EIC Ambassador for Eastern Europe
|
EIC Ambassador for Eastern Europe | Total investments: 3 | Find email | |
|
Monique Calisti
Expert evaluator and reviewer
|
Expert evaluator and reviewer | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AGADE
|
AGADE specialising in robotic exoskeletons. The company created its first product, AGADEXO, which can significantly reduce muscle fatigue and the risk of injury associated with repetitive and dynamic activities. They provide variable support, eliminating the effect of gravity on human limbs and allowing movements comparable to those possible in azero-g environment. | $9M / Venture - Series Unknown / Apr 14, 2022 | |
BroadBit Batteries
|
BroadBit Batteries is developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy. They are developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy.They have already made high-performance lab samples and are now commercializing the technologyfor next-generation electric vehicles, portable electronics, starters, and grid energy storage. | $2.8M / Grant / Dec 20, 2021 | |
Aenitis Technologies
|
Created in July 2014, Aenitis Technologies is a French start-up resulting from the work of Mauricio HOYOS and Jean-Luc AIDER, both CNRS researchers at the PMMH Laboratory (Physics and Mechanics of Heterogeneous Media at the ESPCI ParisTech, a research engineer’s school in Paris. The company focuses on medical devices’ area, where their breakthroughtechnologies are highly promising. Aenitis Technologies is developing innovative separation, manipulation and filtration of biological elements solutions, based on acoustophoresis technologies. The company first focuses on technological solutions that will revolutionize current practices in Public Health. Aenitis Technologies aims to become a world leader in filtering / separating solutions by acoustophoresis. | Grant / Jun 16, 2021 | |
Orthox Ltd.
|
Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and will shortly enter clinical trials. FibroFix™ technology will then be rolled out to treat other joints and Orthox also has pipeline developments beyond orthopaedics in which strength and tissue regeneration are key. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™. | $2.8M / Grant / Jul 01, 2020 | |
Vital Beats
|
Vital Beats combines participatory design and data science with nordic aesthetics to ensure that it’s both enjoyable and valuable to use their platform. Their platform never sleeps and constantly triages every cardiac device patient using their patent-pending technique. | $2.3M / Seed / Jul 01, 2020 | |
Brevel
|
Brevel developed a disruptive cultivation technology for sustainable, low cost and high quality production of microalgae for various yet untapped markets. The technology is based on high-tech indoor, sterile and fully automated systems which are illuminated from within at high intensity. The technology enables the surprising results of more than90% cost reduction and up to 200 higher yields compared to current alternatives. Brevel is using the advantageous production capabilities to enter multiple markets where microalgae derived products are needed. | $1.3M / Grant / Apr 01, 2020 | |
QDevil
|
QDevil aim of enhancing the science in quantum electronics labs, by enabling scientists to focus their effort on the science, instead of constructing auxiliary equipment that already has been developed in other labs.The products of QDevil have been used and thoroughly tested in some of the world’s leading quantum electronics labs. The initialproduct of QDevil is the QFilter, which has been developed and tested at Harvard University and University of Copenhagen for over five years. | $1.1M / Grant / Mar 01, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Climate VC Funds
33,091 investors
FAQ
What does EISMEA invest in?
EISMEA invests primarily in Health Care, Biotechnology and Medical startups, most often at Grant and Seed stage. Most of the 7 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact EISMEA?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EISMEA?
The team at EISMEA includes Cristian Dascalu (EIC Ambassador for Eastern Europe) and Monique Calisti (Expert evaluator and reviewer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
